Related Experiment Videos
Preclinical comparative evaluation of aminoglycosides
Chemioterapia : International Journal of the Mediterranean Society of Chemotherapy
|December 1, 1984
Summary
Netilmicin demonstrated superior in vitro activity against common bacterial pathogens compared to other aminoglycosides. It also showed significant efficacy against gentamicin-resistant strains, indicating broad clinical potential.
Area of Science:
- Microbiology
- Pharmacology
- Infectious Diseases
Background:
- Aminoglycoside antibiotics are crucial for treating serious bacterial infections.
- Emergence of antibiotic resistance necessitates evaluation of existing and new agents.
- Comparative in vitro analysis guides clinical selection of antibiotics.
Purpose of the Study:
- To compare the in vitro activity of five aminoglycosides: gentamicin, sisomicin, tobramycin, amikacin, and netilmicin.
- To evaluate their efficacy against clinical isolates of Pseudomonas, Enterobacteriaceae, and Gram-positive cocci.
- To assess activity against gentamicin-resistant bacterial strains.
Main Methods:
- Agar dilution technique following I.C.S. recommendations.
- Testing against 283 clinical bacterial isolates.
- Determination of minimum inhibitory concentrations (MICs) and rate of killing curves.
- Calculation of therapeutic index.
Main Results:
- Netilmicin exhibited the highest potency by weight against E. coli, K. pneumoniae, Enterobacter, Serratia spp., and Staphylococcus aureus.
- Sisomicin and tobramycin showed the lowest MICs against Pseudomonas aeruginosa.
- Amikacin displayed the widest spectrum of activity but overall lower potency.
- Netilmicin was effective against gentamicin-resistant strains, comparable or superior to amikacin, with a high therapeutic index.
Conclusions:
- Netilmicin is a highly potent aminoglycoside with broad-spectrum activity, including against gentamicin-resistant bacteria.
- The study highlights netilmicin's favorable therapeutic index, suggesting clinical utility.
- Comparative in vitro data are essential for optimizing antibiotic therapy selection.